Do β-adrenoreceptor blocking drugs associate with reduced risk of symptomatic osteoarthritis and total joint replacement in the general population? A primary care-based, prospective cohort study using the Clinical Practice Research Datalink

Georgina Nakafero, Matthew Grainge, Ana Valdes, Nick Townsend, Christian Mallen, Weiya Zhang, Michael Doherty, Mamas A. Mamas, Abhishek Abhishek

Research output: Contribution to journalArticle

Abstract

Introduction: To investigate if β-adrenoreceptor blocking drug (β-blocker) prescription reduces the risk of knee or hip osteoarthritis, total joint replacement and analgesic prescription. Setting: Primary care. Methods and analysis: This is a cohort study using data from the Clinical Practice Research Datalink. Two separate analyses will be performed. Study 1 will be on the association between β-blocker prescription and incident knee/hip osteoarthritis. Inclusion criteria will be age ≥40 years. Exposed participants will be those with ≥2 continuous β-blocker prescriptions, and the index date will be the date of the first prescription of β-blocker. Unexposed participants will include up to four controls matched for age, sex, general practice surgery and propensity score for β-blocker prescription. Exclusion criteria will include contraindications to β-blockers, consultations for osteoarthritis or potent analgesic prescription before the index date. Outcomes will be knee osteoarthritis (primary outcome), hip osteoarthritis, knee pain and hip pain. Study 2 will be on the association between β-blocker prescription and total joint replacement and analgesic prescription in people with osteoarthritis. Inclusion criteria will be age ≥40 years, knee or hip osteoarthritis, and index date will be as in study 1. Unexposed participants will be as in study 1, additionally matched for consultation for knee or hip osteoarthritis prior to the index date. Exclusion criteria will include contraindications to β-blockers and osteoarthritis in other joints prior to the index date. Outcomes will be total knee replacement (primary outcome), total hip replacement and new analgesic prescription. Statistical analysis: Kaplan-Meier curves will be plotted, and Cox proportional HRs and 95% CIs will be calculated. Stratified analysis will be performed by class of β-blocker, intrinsic sympathomimetic effect and indication(s) for prescription. Ethics and dissemination: This study was ethically approved by the Independent Scientific Advisory Committee of the Medicines and Healthcare Authority (Ref 18-227R). The results of this study will be published in peer-reviewed journals and presented at conferences. Summary: This prospective cohort study will evaluate the analgesic potential of commonly used drugs for osteoarthritis pain.

Original languageEnglish
Article numbere032050
Pages (from-to)e032050
JournalBMJ Open
Volume9
Issue number8
DOIs
Publication statusPublished - 1 Aug 2019

Keywords

  • analgesia
  • anti-hypertensives
  • osteoarthritis
  • pain
  • total joint replacement

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Do β-adrenoreceptor blocking drugs associate with reduced risk of symptomatic osteoarthritis and total joint replacement in the general population? A primary care-based, prospective cohort study using the Clinical Practice Research Datalink. / Nakafero, Georgina; Grainge, Matthew; Valdes, Ana; Townsend, Nick; Mallen, Christian; Zhang, Weiya; Doherty, Michael; Mamas, Mamas A.; Abhishek, Abhishek.

In: BMJ Open, Vol. 9, No. 8, e032050, 01.08.2019, p. e032050.

Research output: Contribution to journalArticle

Nakafero, Georgina ; Grainge, Matthew ; Valdes, Ana ; Townsend, Nick ; Mallen, Christian ; Zhang, Weiya ; Doherty, Michael ; Mamas, Mamas A. ; Abhishek, Abhishek. / Do β-adrenoreceptor blocking drugs associate with reduced risk of symptomatic osteoarthritis and total joint replacement in the general population? A primary care-based, prospective cohort study using the Clinical Practice Research Datalink. In: BMJ Open. 2019 ; Vol. 9, No. 8. pp. e032050.
@article{e90e27b0ef654e47a62c6db33563f499,
title = "Do β-adrenoreceptor blocking drugs associate with reduced risk of symptomatic osteoarthritis and total joint replacement in the general population? A primary care-based, prospective cohort study using the Clinical Practice Research Datalink",
abstract = "Introduction: To investigate if β-adrenoreceptor blocking drug (β-blocker) prescription reduces the risk of knee or hip osteoarthritis, total joint replacement and analgesic prescription. Setting: Primary care. Methods and analysis: This is a cohort study using data from the Clinical Practice Research Datalink. Two separate analyses will be performed. Study 1 will be on the association between β-blocker prescription and incident knee/hip osteoarthritis. Inclusion criteria will be age ≥40 years. Exposed participants will be those with ≥2 continuous β-blocker prescriptions, and the index date will be the date of the first prescription of β-blocker. Unexposed participants will include up to four controls matched for age, sex, general practice surgery and propensity score for β-blocker prescription. Exclusion criteria will include contraindications to β-blockers, consultations for osteoarthritis or potent analgesic prescription before the index date. Outcomes will be knee osteoarthritis (primary outcome), hip osteoarthritis, knee pain and hip pain. Study 2 will be on the association between β-blocker prescription and total joint replacement and analgesic prescription in people with osteoarthritis. Inclusion criteria will be age ≥40 years, knee or hip osteoarthritis, and index date will be as in study 1. Unexposed participants will be as in study 1, additionally matched for consultation for knee or hip osteoarthritis prior to the index date. Exclusion criteria will include contraindications to β-blockers and osteoarthritis in other joints prior to the index date. Outcomes will be total knee replacement (primary outcome), total hip replacement and new analgesic prescription. Statistical analysis: Kaplan-Meier curves will be plotted, and Cox proportional HRs and 95{\%} CIs will be calculated. Stratified analysis will be performed by class of β-blocker, intrinsic sympathomimetic effect and indication(s) for prescription. Ethics and dissemination: This study was ethically approved by the Independent Scientific Advisory Committee of the Medicines and Healthcare Authority (Ref 18-227R). The results of this study will be published in peer-reviewed journals and presented at conferences. Summary: This prospective cohort study will evaluate the analgesic potential of commonly used drugs for osteoarthritis pain.",
keywords = "analgesia, anti-hypertensives, osteoarthritis, pain, total joint replacement",
author = "Georgina Nakafero and Matthew Grainge and Ana Valdes and Nick Townsend and Christian Mallen and Weiya Zhang and Michael Doherty and Mamas, {Mamas A.} and Abhishek Abhishek",
note = "{\circledC} Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.",
year = "2019",
month = "8",
day = "1",
doi = "10.1136/bmjopen-2019-032050",
language = "English",
volume = "9",
pages = "e032050",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Do β-adrenoreceptor blocking drugs associate with reduced risk of symptomatic osteoarthritis and total joint replacement in the general population? A primary care-based, prospective cohort study using the Clinical Practice Research Datalink

AU - Nakafero, Georgina

AU - Grainge, Matthew

AU - Valdes, Ana

AU - Townsend, Nick

AU - Mallen, Christian

AU - Zhang, Weiya

AU - Doherty, Michael

AU - Mamas, Mamas A.

AU - Abhishek, Abhishek

N1 - © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Introduction: To investigate if β-adrenoreceptor blocking drug (β-blocker) prescription reduces the risk of knee or hip osteoarthritis, total joint replacement and analgesic prescription. Setting: Primary care. Methods and analysis: This is a cohort study using data from the Clinical Practice Research Datalink. Two separate analyses will be performed. Study 1 will be on the association between β-blocker prescription and incident knee/hip osteoarthritis. Inclusion criteria will be age ≥40 years. Exposed participants will be those with ≥2 continuous β-blocker prescriptions, and the index date will be the date of the first prescription of β-blocker. Unexposed participants will include up to four controls matched for age, sex, general practice surgery and propensity score for β-blocker prescription. Exclusion criteria will include contraindications to β-blockers, consultations for osteoarthritis or potent analgesic prescription before the index date. Outcomes will be knee osteoarthritis (primary outcome), hip osteoarthritis, knee pain and hip pain. Study 2 will be on the association between β-blocker prescription and total joint replacement and analgesic prescription in people with osteoarthritis. Inclusion criteria will be age ≥40 years, knee or hip osteoarthritis, and index date will be as in study 1. Unexposed participants will be as in study 1, additionally matched for consultation for knee or hip osteoarthritis prior to the index date. Exclusion criteria will include contraindications to β-blockers and osteoarthritis in other joints prior to the index date. Outcomes will be total knee replacement (primary outcome), total hip replacement and new analgesic prescription. Statistical analysis: Kaplan-Meier curves will be plotted, and Cox proportional HRs and 95% CIs will be calculated. Stratified analysis will be performed by class of β-blocker, intrinsic sympathomimetic effect and indication(s) for prescription. Ethics and dissemination: This study was ethically approved by the Independent Scientific Advisory Committee of the Medicines and Healthcare Authority (Ref 18-227R). The results of this study will be published in peer-reviewed journals and presented at conferences. Summary: This prospective cohort study will evaluate the analgesic potential of commonly used drugs for osteoarthritis pain.

AB - Introduction: To investigate if β-adrenoreceptor blocking drug (β-blocker) prescription reduces the risk of knee or hip osteoarthritis, total joint replacement and analgesic prescription. Setting: Primary care. Methods and analysis: This is a cohort study using data from the Clinical Practice Research Datalink. Two separate analyses will be performed. Study 1 will be on the association between β-blocker prescription and incident knee/hip osteoarthritis. Inclusion criteria will be age ≥40 years. Exposed participants will be those with ≥2 continuous β-blocker prescriptions, and the index date will be the date of the first prescription of β-blocker. Unexposed participants will include up to four controls matched for age, sex, general practice surgery and propensity score for β-blocker prescription. Exclusion criteria will include contraindications to β-blockers, consultations for osteoarthritis or potent analgesic prescription before the index date. Outcomes will be knee osteoarthritis (primary outcome), hip osteoarthritis, knee pain and hip pain. Study 2 will be on the association between β-blocker prescription and total joint replacement and analgesic prescription in people with osteoarthritis. Inclusion criteria will be age ≥40 years, knee or hip osteoarthritis, and index date will be as in study 1. Unexposed participants will be as in study 1, additionally matched for consultation for knee or hip osteoarthritis prior to the index date. Exclusion criteria will include contraindications to β-blockers and osteoarthritis in other joints prior to the index date. Outcomes will be total knee replacement (primary outcome), total hip replacement and new analgesic prescription. Statistical analysis: Kaplan-Meier curves will be plotted, and Cox proportional HRs and 95% CIs will be calculated. Stratified analysis will be performed by class of β-blocker, intrinsic sympathomimetic effect and indication(s) for prescription. Ethics and dissemination: This study was ethically approved by the Independent Scientific Advisory Committee of the Medicines and Healthcare Authority (Ref 18-227R). The results of this study will be published in peer-reviewed journals and presented at conferences. Summary: This prospective cohort study will evaluate the analgesic potential of commonly used drugs for osteoarthritis pain.

KW - analgesia

KW - anti-hypertensives

KW - osteoarthritis

KW - pain

KW - total joint replacement

UR - http://www.scopus.com/inward/record.url?scp=85070218829&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2019-032050

DO - 10.1136/bmjopen-2019-032050

M3 - Article

VL - 9

SP - e032050

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 8

M1 - e032050

ER -